Literature DB >> 18173768

Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors.

Antonei B Csoka1, A Csoka, Audrey Bahrick, Olli-Pekka Mehtonen.   

Abstract

INTRODUCTION: Sexual dysfunctions such as low libido, anorgasmia, genital anesthesia, and erectile dysfunction are very common in patients taking selective serotonin reuptake inhibitors (SSRIs). It has been assumed that these side effects always resolve after discontinuing treatment, but recently, four cases were presented in which sexual function did not return to baseline. Here, we describe three more cases. Case #1: A 29-year-old with apparently permanent erectile dysfunction after taking fluoxetine 20 mg once daily for a 4-month period in 1996. Case #2: A 44-year-old male with persistent loss of libido, genital anesthesia, ejaculatory anhedonia, and erectile dysfunction after taking 20-mg once daily citalopram for 18 months. Case #3: A 28-year-old male with persistent loss of libido, genital anesthesia, and ejaculatory anhedonia since taking several different SSRIs over a 2-year period from 2003-2005.
RESULTS: No psychological issues related to sexuality were found in any of the three cases, and all common causes of sexual dysfunction such as decreased testosterone, increased prolactin or diabetes were ruled out. Erectile capacity is temporarily restored for Case #1 with injectable alprostadil, and for Case #2 with oral sildenafil, but their other symptoms remain. Case #3 has had some reversal of symptoms with extended-release methylphenidate, although it is not yet known if these prosexual effects will persist when the drug is discontinued.
CONCLUSION: SSRIs can cause long-term effects on all aspects of the sexual response cycle that may persist after they are discontinued. Mechanistic hypotheses including persistent endocrine and epigenetic gene expression alterations were briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18173768     DOI: 10.1111/j.1743-6109.2007.00630.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  22 in total

Review 1.  Advances in understanding and treating premature ejaculation.

Authors:  Theodore R Saitz; Ege Can Serefoglu
Journal:  Nat Rev Urol       Date:  2015-10-27       Impact factor: 14.432

2.  Fluoxetine potentiation of methylphenidate-induced neuropeptide expression in the striatum occurs selectively in direct pathway (striatonigral) neurons.

Authors:  Vincent Van Waes; Betsy Carr; Joel A Beverley; Heinz Steiner
Journal:  J Neurochem       Date:  2012-07-23       Impact factor: 5.372

3.  Depression and sexual dysfunction among HIV-positive and HIV-negative men who have sex with men: mediation by use of antidepressants and recreational stimulants.

Authors:  Trevor A Hart; Brian Mustanski; Daniel T Ryan; Pamina M Gorbach; Ron D Stall; Pamela J Surkan; Michael Plankey
Journal:  Arch Sex Behav       Date:  2014-03-27

Review 4.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

5.  Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum.

Authors:  Vincent Van Waes; Joel Beverley; Michela Marinelli; Heinz Steiner
Journal:  Eur J Neurosci       Date:  2010-08       Impact factor: 3.386

6.  Fluoxetine-induced decrements in sexual responses of female rats and hamsters are reversed by 3α,5α-THP.

Authors:  Cheryl A Frye; Madeline E Rhodes
Journal:  J Sex Med       Date:  2010-04-20       Impact factor: 3.802

Review 7.  New insights on premature ejaculation: a review of definition, classification, prevalence and treatment.

Authors:  Ege C Serefoglu; Theodore R Saitz
Journal:  Asian J Androl       Date:  2012-10-15       Impact factor: 3.285

Review 8.  Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior.

Authors:  Heinz Steiner; Brandon L Warren; Vincent Van Waes; Carlos A Bolaños-Guzmán
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

9.  Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: potential role for 5-HT1B receptor.

Authors:  Vincent Van Waes; Sarah Ehrlich; Joel A Beverley; Heinz Steiner
Journal:  Neuropharmacology       Date:  2014-09-16       Impact factor: 5.250

Review 10.  Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants.

Authors:  Heinz Steiner; Vincent Van Waes
Journal:  Prog Neurobiol       Date:  2012-10-17       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.